H.R. 10359, Pharmaceutical Industry Subsidy Extension. Quorum's AI analysis reads it as a trade-off: gains for some, costs for others.
H.R. 10359 · Mixed
What it does
This bill makes permanent the FDA's authority to award priority review vouchers (fast-track approval) to companies developing drugs for rare pediatric diseases. Currently, that authority expires; the bill removes the sunset clause so it never lapses.
The analysis names pharmaceutical companies developing rare pediatric disease treatments — and 1 more group — among the beneficiaries.
The trade-off
Priority review vouchers are tradeable assets with significant market value; permanent extension locks in an indefinite subsidy to pharmaceutical companies without periodic congressional reauthorization or performance review.
Transparency scores 95%, with a medium warning level and no provisions unrelated to the bill's subject.
Who is behind it
Filed by Gus Bilirakis. Cosponsored by Jake Auchincloss, Josh Riley, Kat Cammack and Kevin Mullin.
The week in bills
One email, Sunday: what Congress passed, what it changed, and who paid.
One link arrives to confirm the address. It is used for this email and nothing else, and every issue carries an unsubscribe link.